Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

Table 3 Univariate analysis of clinicopathological data and A-FABP expression in relation to RFS and PFS of patients with NMIBC

	HR	RFS		P	HR	PFS		P
		95% CI				95% CI
		–	+			–	+
pTa
Sex (F)	0.60	0.24	1.53	0.280	0.04	0.00	22.1	0.111
Age (> 72)	1.21	0.65	2.28	0.547	1.16	0.38	3.54	0.800
Histology (variants)	0.99	0.14	7.26	0.997	0.05	0.00	404,941.26	0.574
Grade (for each change of category)	1.14	0.71	1.83	0.564	1.27	0.54	2.99	0.763
Cis (yes)				NA				NA
A-FABP negativity	0.55	0.3	1.02	0.055	0.34	0.10	0.97	0.045
pT1
Sex (F)	0.04	0.00	16.09	0.102	4.34	0.41	46.4	0.187
Age (> 72)	2.04	0.84	5.00	0.110	0.75	0.12	4.6	0.756
Histology (variants)	0.04	0.00	129.34	0.245	0.05	0.00	18,539,252.39	0.646
Grade (for each change of category)	0.58	0.17	1.96	0.373	25.34	0.00	2,740,610.19	0.392
Cis (yes)	0.03	0.00	3.65	0.151	0.04	0.00	1840.31	0.350
A-FABP negativity	1.22	0.51	2.91	0.648	0.39	0.04	3.48	0.380
pTa/pT1
Sex (F)	0.43	0.17	1.09	0.074	0.38	0.05	2.86	0.347
Age (> 72)	1.52	0.92	2.51	0.104	1.01	0.39	2.63	0.976
Histology (variants)	0.48	0.07	3.47	0.468	0.05	0.00	11,861.4	0.631
Stage (pT1)	1.71	1.01	2.9	0.048	1.06	0.38	2.99	0.907
Grade (for each change of category)	1.28	0.89	1.83	0.183	1.27	0.65	2.48	0.487
Cis (yes)	0.05	0.00	5.19	0.201	1.3	0.17	9.79	0.797
A-FABP negativity	0.66	0.40	1.08	0.099	0.36	0.13	0.96	0.041

*Abbreviations: NMIBC (pTa and pT1) Non-muscle invasive bladder cancer, CI Confidence interval, HR Hazard ratio, RFS Recurrence-free survival, PFS Progression-free survival

ISSN: 1471-2407